A newly published study in the journal ACS Applied Materials & Interfaces describes a laboratory formulation designed to deliver semaglutide — the active ingredient in Ozempic and Wegovy — as an oral pill rather than an injection. The research is early-stage, but it targets one of the most persistent obstacles in GLP-1 drug development: getting a fragile peptide drug to survive the digestive system.
What the Research Actually Tested
Delivering peptide-based drugs like semaglutide by mouth has long been considered extremely difficult. The digestive tract breaks down proteins before they can be absorbed, and the lining of the gut is largely impermeable to large molecules. According to the published abstract, researchers developed a solid enteric formulation using sorbic acid-choline ionic liquids (ILs) designed to protect semaglutide from gastrointestinal degradation and improve its ability to cross the intestinal wall. The goal is to increase what scientists call bioavailability — the share of a drug dose that actually reaches the bloodstream.
Why This Is Hard — and Why It Matters
The challenges the study describes are real and well-documented. GLP-1 receptor agonists are peptides, meaning they are chains of amino acids that stomach acid and digestive enzymes rapidly destroy. Current injectable versions of semaglutide (Ozempic, Wegovy) sidestep this problem entirely by bypassing the gut. A low-dose oral semaglutide tablet called Rybelsus already exists for type 2 diabetes, but it uses a different absorption-enhancing approach and requires strict dosing conditions — taken on an empty stomach with a small sip of water and a 30-minute wait before eating. Higher-dose oral options that could match injectable efficacy for weight loss remain an active area of research.
What This Means for Patients Right Now
It is important to be clear about what this study is and is not. This is a preclinical materials science publication — researchers developed and characterized a new formulation. It has not been tested in large human clinical trials, it has not been reviewed by the FDA, and it is not a product that will be available soon. The headline framing of "no more weekly shots" goes well beyond what the published abstract supports. Patients currently taking injectable semaglutide or tirzepatide should not interpret this as a signal to change their treatment.
Key takeaway: This study describes promising lab-stage technology, not a new approved drug. An oral GLP-1 pill that fully replaces injections for weight loss or diabetes remains in early research — consult your prescriber before making any changes to your current regimen.
What to Watch Going Forward
Ionic liquid-based drug delivery is a growing area of pharmaceutical research, and publications like this one contribute to a longer pipeline that could eventually yield new oral formulations. Novo Nordisk, the maker of Ozempic and Wegovy, has publicly invested in next-generation oral GLP-1 development. Any future candidate based on technology like this would need to advance through preclinical animal studies, then Phase 1, 2, and 3 human trials before regulatory review. That process typically takes many years. Patients and clinicians should watch for announcements of human trials as the meaningful next milestone.
Frequently Asked Questions
This research represents an interesting scientific step, but it remains far from clinical use. If you have questions about your current GLP-1 medication, alternative formulations, or what emerging research might mean for your treatment plan, speak with your prescriber or pharmacist for personalized guidance.
- Peer-reviewed journal article, 'An Ionic Liquid-Based Enteric Formulation for Enhanced Oral Delivery of Semaglutide in Type 2 Diabetes Mellitus,' ACS Applied Materials & Interfaces, date not specified in source material.